Genmab A/S (CPH:GMAB)
Denmark
· Delayed Price · Currency is DKK | Market Cap | 84.20B |
| Revenue (ttm) | 21.53B |
| Net Income (ttm) | 7.84B |
| Shares Out | 63.55M |
| EPS (ttm) | 121.36 |
| PE Ratio | 10.92 |
| Forward PE | 12.72 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 107,941 |
| Average Volume | 191,212 |
| Open | 1,343.00 |
| Previous Close | 1,325.00 |
| Day's Range | 1,320.50 - 1,358.50 |
| 52-Week Range | 1,300.00 - 2,137.00 |
| Beta | 0.90 |
| RSI | 29.96 |
| Earnings Date | May 8, 2025 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no... [Read more]
Financial Performance
In 2024, Genmab's revenue was 21.53 billion, an increase of 30.67% compared to the previous year's 16.47 billion. Earnings were 7.84 billion, an increase of 80.24%.
Financial StatementsNews
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.
Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle) Genmab categorically refutes allegations and will vigorously...
DARZALEX Continues to Redefine Multiple Myeloma Treatment with Robust Market Performance | DelveInsight
DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory patient...
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan (Rina-S®), an investigational fola...
Coinbase, Apple And Robinhood Are Among Top Large-Cap Losers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?
These large-cap stocks were the worst performers in the last week. Are they in your portfolio? Teradyne (NASDAQ: TER) shares dipped 20.08%. The company agreed to acquire Photonic IC Testing Company Q...
Genmab: GEN3014's Demise And Implications For The HexaBody Platform
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, th...
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S' Annual General Meeting held on March 12, 2025, the Company's Board of Directors met to consti...
Passing of Genmab A/S' Annual General Meeting
Company Announcement At Genmab A/S' Annual General Meeting held today March 12, 2025, the Annual Report for 2024 was approved Discharge was given to the Board of Directors and the Executive Management...
Genmab upgraded to Outperform at William Blair
Johnson and Johnson will not exercise worldwide license option for HexaBody-CD38, says Genmab
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop,...
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
Company Announcement Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue fu...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; March 4, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, thi...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 614,676 restricted stock units to members of management and empl...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; February 25, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,058 shares as a consequence of the exercise of employee warrants. The incr...
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
Media Release COPENHAGEN, Denmark; February 20, 2025 Approval based on results from two Phase 1/2 EPCORE ® clinical trials, which demonstrated strong and durable efficacy in patients with relapsed or ...
Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference
Media Release COPENHAGEN, Denmark; February 19, 2025 Genmab A/S (Nasdaq: GMAB) announced today that its C hief F inancial O fficer Anthony Pagano and C hief D evelopment O fficer Judith Klimovsky wil...
Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon
Genmab A/S (GMAB) Q4 2024 Earnings Conference Call Transcript
Genmab A/S 2024 Q4 - Results - Earnings Call Presentation
Notice to Convene the Annual General Meeting of Genmab A/S
Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025 COPENHAGEN, Denmark; February 13, 2025 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Wedn...
Genmab AS (GMAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...
Genmab AS (GMAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Acquisitions Propel Future Prospects
Q4 2024 Genmab A/S Earnings Call Transcript
Q4 2024 Genmab A/S Earnings Call Transcript
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
Media Release COPENHAGEN, Denmark; February 12, 2025 Genmab filed Form 20-F for the financial year 2024 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report ...